


A 100-year perspective on Myelodysplastic syndromes: moving towards personalized management



Higher risk MDS

- ▶ Treatment dominated by monotherapy with hypomethylating agents
- ▶ Novel combinations are currently being evaluated in clinical trials



Lower risk MDS

- ▶ Erythropoietic agents (ESAs) is first-line treatment for the anemia
- ▶ Luspatercept has shown promise as second-line therapy for sideroblastic MDS
- ▶ Lenalidomide is established second-line treatment for del(5q) lower-risk MDS